These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3805013)

  • 1. Antithrombin-III Denver, a reactive site variant.
    Stephens AW; Thalley BS; Hirs CH
    J Biol Chem; 1987 Jan; 262(3):1044-8. PubMed ID: 3805013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactive site peptide structural similarity between heparin cofactor II and antithrombin III.
    Griffith MJ; Noyes CM; Church FC
    J Biol Chem; 1985 Feb; 260(4):2218-25. PubMed ID: 3838304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombin-III-Hamilton, Ala 382 to Thr: an antithrombin-III variant that acts as a substrate but not an inhibitor of alpha-thrombin and factor Xa.
    Austin RC; Rachubinski RA; Ofosu FA; Blajchman MA
    Blood; 1991 May; 77(10):2185-9. PubMed ID: 2029579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal antithrombin III with defective serine protease binding (antithrombin III "Denver").
    Sambrano JE; Jacobson LJ; Reeve EB; Manco-Johnson MJ; Hathaway WE
    J Clin Invest; 1986 Mar; 77(3):887-93. PubMed ID: 3512602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding.
    Jørgensen M; Petersen LC; Thorsen S
    J Lab Clin Med; 1984 Aug; 104(2):245-56. PubMed ID: 6747440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression in a cell-free system of normal and variant forms of human antithrombin III. Ability to bind heparin and react with alpha-thrombin.
    Austin RC; Rachubinski RA; Fernandez-Rachubinski F; Blajchman MA
    Blood; 1990 Oct; 76(8):1521-9. PubMed ID: 2207328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombin Sheffield: amino acid substitution at the reactive site (Arg393 to His) causing thrombosis.
    Lane DA; Erdjument H; Flynn A; Di Marzo V; Panico M; Morris HR; Greaves M; Dolan G; Preston FE
    Br J Haematol; 1989 Jan; 71(1):91-6. PubMed ID: 2917133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombin Glasgow, 393 Arg to His: a P1 reactive site variant with increased heparin affinity but no thrombin inhibitory activity.
    Owen MC; Beresford CH; Carrell RW
    FEBS Lett; 1988 Apr; 231(2):317-20. PubMed ID: 3360140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single amino acid substitutions in the reactive site of antithrombin leading to thrombosis. Congenital substitution of arginine 393 to cysteine in antithrombin Northwick Park and to histidine in antithrombin Glasgow.
    Erdjument H; Lane DA; Panico M; Di Marzo V; Morris HR
    J Biol Chem; 1988 Apr; 263(12):5589-93. PubMed ID: 3162733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin binding defect in a new antithrombin III variant: Rouen, 47 Arg to His.
    Owen MC; Borg JY; Soria C; Soria J; Caen J; Carrell RW
    Blood; 1987 May; 69(5):1275-9. PubMed ID: 3567355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purification and further characterization of antithrombin III Milano: lack of reactivity with thrombin.
    Wolf M; Boyer-Neumann C; Meyer D; Tripodi A; Mannucci PM; Larrieu MJ
    Thromb Haemost; 1987 Oct; 58(3):888-92. PubMed ID: 3433251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation and characterization of an antithrombin III variant with reduced carbohydrate content and enhanced heparin binding.
    Peterson CB; Blackburn MN
    J Biol Chem; 1985 Jan; 260(1):610-5. PubMed ID: 3965464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The N-terminal domain of antithrombin-III is essential for heparin binding and complex-formation with, but not cleavage by, alpha-thrombin.
    Austin RC; Sheffield WP; Rachubinski RA; Blajchman MA
    Biochem J; 1992 Mar; 282 ( Pt 2)(Pt 2):345-51. PubMed ID: 1546950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a novel recombinant serpin with potential antithrombotic properties.
    Hopkins PC; Crowther DC; Carrell RW; Stone SR
    J Biol Chem; 1995 May; 270(20):11866-71. PubMed ID: 7744836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The heparin-binding site of antithrombin III. Identification of a critical tryptophan in the amino acid sequence.
    Blackburn MN; Smith RL; Carson J; Sibley CC
    J Biol Chem; 1984 Jan; 259(2):939-41. PubMed ID: 6693405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation and characterization of a hereditary abnormal antithrombin III 'Antithrombin III Toyama'.
    Koide T; Takahashi K; Odani S; Ono T; Sakuragawa N
    Thromb Res; 1983 Jul; 31(2):319-28. PubMed ID: 6636046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Site-directed mutagenesis of the reactive center (serine 394) of antithrombin III.
    Stephens AW; Siddiqui A; Hirs CH
    J Biol Chem; 1988 Nov; 263(31):15849-52. PubMed ID: 3141397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutagenesis of thrombin selectively modulates inhibition by serpins heparin cofactor II and antithrombin III. Interaction with the anion-binding exosite determines heparin cofactor II specificity.
    Sheehan JP; Wu Q; Tollefsen DM; Sadler JE
    J Biol Chem; 1993 Feb; 268(5):3639-45. PubMed ID: 8429040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombin Glasgow II: alanine 382 to threonine mutation in the serpin P12 position, resulting in a substrate reaction with thrombin.
    Ireland H; Lane DA; Thompson E; Walker ID; Blench I; Morris HR; Freyssinet JM; Grunebaum L; Olds R; Thein SL
    Br J Haematol; 1991 Sep; 79(1):70-4. PubMed ID: 1911389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of an abnormal antithrombin (Milano 2) with defective thrombin binding.
    Tripodi A; Krachmalnicoff A; Mannucci PM
    Thromb Haemost; 1986 Dec; 56(3):349-52. PubMed ID: 3563966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.